Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool

Table 4 Costing summary of HPV vaccination in 2020–2024 (2019 US dollars)

	2020	2021	2022	2023	2024	Total	Percentage
Coverage
First dose	80%	82%	85%	87%	90%	85%	NA
Second dose	70%	72%	75%	80%	85%	77%
Drop-out	12.5%	12.2%	11.8%	8%	5.6%	12.5%
Financial
Startup (US$000s) (annualized)
Microplanning	25	25	25	25	25	125	0.7
Training	78	78	78	78	78	386	2.1
Sensitization	78	78	78	78	78	390	2.1
Recurrent (US$000s)
Vaccine procurement^a	1853	1962	2101	2261	2443	10,621	58.1
Service delivery	1066	1128	1208	1302	1405	6108	33.4
Monitoring and supervision	129	129	129	129	129	644	3.5
Total financial costs (US$000s)	3229	3400	3619	3874	4158	18275	100%
Economic
Startup (US$000s) (annualized)
Microplanning	30	30	30	30	30	138	0.3
Training	105	105	105	105	105	481	1.0
Sensitization	94	94	94	94	94	429	0.9
Recurrent (US$000s)
Vaccine procurement	5899	6244	6688	7200	7775	33,806	71.4
Service delivery	1984	2100	2250	2422	2615	11,370	24.0
Monitoring and supervision	220	220	220	220	220	1102	2.3
Total economic costs (US$000s)	8332	8793	9387	10,071	10,839	47,327	100%
Number of FIGs	469,634	497,998	534,646	588,497	644,036	2,734,810	NA
Financial cost per FIG with vaccine costs	NA^b	NA^b	NA^b	NA^b	NA^b	$6.68	NA
Economic cost per FIG with vaccine costs	NA^b	NA^b	NA^b	NA^b	NA^b	$17.31	NA

FIG fully immunized girls; costs reported in 2019 US dollars (US$)
^aRefers to 20% vaccine purchase and freight, handling and insurance charges
^bDue to substantial one-time costs necessarily being spread over the 5 years and personnel costs being calculated per vaccination, the per FIG annual costs would not adequately reflect service volume. See instead the aggregate costs divided by the total numbers of fully immunized girls for the 5 years in the “Total” column

ISSN: 1741-7015